Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2016 May 17;9(1):29.
doi: 10.1186/s13048-016-0237-8.

GnRH antagonist rescue protocol combined with cabergoline versus cabergoline alone in the prevention of ovarian hyperstimulation syndrome: a randomized controlled trial

Usama M Fouda  1 , Ahmed M Sayed  2 , Hesham S Elshaer  2 , Bahaa Eldin M Hammad  2 , Mona M Shaban  2 , Khaled A Elsetohy  2 , Mohamed A Youssef  2
Affiliations
Randomized Controlled Trial

GnRH antagonist rescue protocol combined with cabergoline versus cabergoline alone in the prevention of ovarian hyperstimulation syndrome: a randomized controlled trial

Usama M Fouda et al. J Ovarian Res. .

Abstract

Background: The aim of this study was to compare the efficacy of antagonist rescue protocol (replacing GnRH agonist with GnRH antagonist and reducing the dose of gonadotropins) combined with cabergoline versus cabergoline alone in the prevention of ovarian hyperstimulation syndrome (OHSS) in patients pretreated with GnRH agonist long protocol who were at high risk for OHSS.

Methods: Two hundred and thirty six patients were randomized in a 1:1 ratio to the cabergoline group or the antagonist rescue combined with cabergoline group. Both groups received oral cabergoline (0.5 mg/day) for eight days beginning on the day of HCG administration. In the antagonist rescue combined with cabergoline group, when the leading follicle reached 16 mm, GnRH agonist (triptorelin) was replaced with GnRH antagonist (cetrorelix acetate) and the dose of HP-uFSH was reduced to 75 IU/day. HCG (5,000 IU/I.M) was administered when the serum estradiol level dropped below 3500 pg/ml. The study was open label and the outcome assessors (laboratory staff and the doctor who performed oocyte retrieval) were blind to treatment allocation.

Results: The incidence of moderate/severe OHSS was significantly lower in the antagonist rescue combined with cabergoline group [5.08 % Vs 13.56 %, P value =0.025, OR = 0.342, 95 % CI, 0.129-0.906]. Four cycles were cancelled in the cabergoline group. There were no significant differences between the groups with respect to the number of retrieved oocytes, metaphase II oocytes, high quality embryos and fertilization rate. Moreover, the implantation and pregnancy rates were comparable between both groups.

Conclusion: GnRH antagonist rescue protocol combined with cabergoline is more effective than cabergoline alone in the prevention of OHSS.

Trial registration: Clinical trial.gov ( NCT02461875 ).

Keywords: Cabergoline; GnRH antagonist; IVF-ET; Ovarian hyperstimulation syndrome.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
The flow of the patients in the study
See this image and copyright information in PMC

References

    1. Kumar P, Sait SF, Sharma A, Kumar M. Ovarian hyperstimulation syndrome. J Hum Reprod Sci. 2011;4:70–5. doi: 10.4103/0974-1208.86080. - DOI - PMC - PubMed
    1. Tang H, Hunter T, Hu Y, Zhai SD, Sheng X, Hart RJ. Cabergoline for preventing ovarian hyperstimulation syndrome. Cochrane Database Syst Rev. 2012;15:CD008605. - PubMed
    1. Kosaka K, Fujiwara H, Tatsumi K, Yoshioka S, Sato Y, Egawa H, et al. Human chorionic gonadotropin (HCG) activates monocytes to produce IL-8 via a different pathway from luteinizing hormone (LH)/HCG receptor system. J Clin Endocrinol Metab. 2002;87:5199–208. doi: 10.1210/jc.2002-020341. - DOI - PubMed
    1. Kosaka K, Fujiwara H, Yoshioka S, Fujii S. Vascular endothelial growth factor production by circulating immune cells is elevated in ovarian hyperstimulation syndrome. Hum Reprod. 2007;22:1647–51. doi: 10.1093/humrep/dem042. - DOI - PubMed
    1. Busso CE, Garcia-Velasco J, Gomez R, Alvarez C, Simón C, Pellicer A. Symposium: update on prediction and management of OHSS. Prevention of OHSS--dopamine agonists. Reprod Biomed Online. 2009;19:43–51. doi: 10.1016/S1472-6483(10)60044-2. - DOI - PubMed

Publication types

Associated data